Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Expands By 97.2%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 35,700 shares, a growth of 97.2% from the June 30th total of 18,100 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily volume of 32,500 shares, the short-interest ratio is currently 1.1 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Cocrystal Pharma in a research note on Tuesday, May 14th.

Cocrystal Pharma Stock Down 0.9 %

Shares of NASDAQ:COCP traded down $0.02 during trading on Friday, hitting $2.20. 9,435 shares of the company were exchanged, compared to its average volume of 27,510. The business’s 50 day moving average is $2.35 and its 200-day moving average is $1.83. Cocrystal Pharma has a 1-year low of $1.33 and a 1-year high of $3.29.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.15. On average, equities analysts predict that Cocrystal Pharma will post -2.02 EPS for the current fiscal year.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.